Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept withdrawal and retreatment in non-radiographic axial spondyloarthritis after 24-week response
NL-OMON42652Phase 4Recruiting
- Sponsor
- Pfizer
- Start
- Aug 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of etanercept in non-radiographic axial spondyloarthritis (nr-axSpA) (3 arms), sponsored by Pfizer. Primary endpoint: Occurrence of flare within 40 weeks after etanercept withdrawal. Started Aug 2016; status: recruiting.
02
Drugs
etanercept
03
Conditions
non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on NL-OMON42652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42652.